{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:22:58Z","timestamp":1793384578663,"version":"4.5.0"},"reference-count":270,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1124\/jpet.122.001234","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T13:05:43Z","timestamp":1654779943000},"page":"133-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":289,"title":["RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies"],"prefix":"10.1016","volume":"384","author":[{"given":"Gavin M.","family":"Traber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Ming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.122.001234_bib1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1124\/jpet.122.001234_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001234_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","article-title":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study","volume":"20","author":"Adams","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1124\/jpet.122.001234_bib4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cpt.1802","article-title":"Pharmacokinetics and pharmacodynamics of the small interfering ribonucleic acid, givosiran, in patients with acute hepatic porphyria","volume":"108","author":"Agarwal","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.122.001234_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fsufs.2019.00023","article-title":"Naturally occurring exosome vesicles as potential delivery vehicle for bioactive compounds","author":"Akuma","year":"2019","journal-title":"Front Sustain Food Syst"},{"key":"10.1124\/jpet.122.001234_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209941","article-title":"A genetically engineered microRNA-34a prodrug demonstrates anti-tumor activity in a canine model of osteosarcoma","volume":"13","author":"Alegre","year":"2018","journal-title":"PLoS One"},{"key":"10.1124\/jpet.122.001234_bib7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Alvarez-Erviti","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1124\/jpet.122.001234_bib8","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1016\/j.febslet.2005.08.070","article-title":"Approaches for chemically synthesized siRNA and vector-mediated RNAi","volume":"579","author":"Amarzguioui","year":"2005","journal-title":"FEBS Lett"},{"key":"10.1124\/jpet.122.001234_bib9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2019.07.002","article-title":"Acute hepatic porphyrias: current diagnosis & management","volume":"128","author":"Anderson","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1124\/jpet.122.001234_bib10","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jb\/mvj091","article-title":"Characterization of extracellular RNAs produced by the marine photosynthetic bacterium Rhodovulum sulfidophilum","volume":"139","author":"Ando","year":"2006","journal-title":"J Biochem"},{"key":"10.1124\/jpet.122.001234_bib11","doi-asserted-by":"crossref","first-page":"908","DOI":"10.4161\/cbt.12.10.17681","article-title":"Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells","volume":"12","author":"Babar","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"10.1124\/jpet.122.001234_bib12","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1158\/0008-5472.CAN-10-2010","article-title":"The promise of microRNA replacement therapy","volume":"70","author":"Bader","year":"2010","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.122.001234_bib13","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001234_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.789931","article-title":"Emerging non-statin treatment options for lowering low-density lipoprotein cholesterol","volume":"8","author":"Bardolia","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1124\/jpet.122.001234_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pharmthera.2017.02.020","article-title":"Exosomes: therapy delivery tools and biomarkers of diseases","volume":"174","author":"Barile","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.122.001234_bib16","first-page":"203","article-title":"Solid-phase synthesis of siRNA oligonucleotides","volume":"11","author":"Beaucage","year":"2008","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1124\/jpet.122.001234_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-59745-248-9_3","article-title":"Synthesis of RNA by in vitro transcription","volume":"703","author":"Beckert","year":"2011","journal-title":"Methods Mol Biol"},{"key":"10.1124\/jpet.122.001234_bib18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Invest New Drugs"},{"key":"10.1124\/jpet.122.001234_bib19","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.molcel.2007.09.028","article-title":"Mammalian mirtron genes","volume":"28","author":"Berezikov","year":"2007","journal-title":"Mol Cell"},{"key":"10.1124\/jpet.122.001234_bib20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/nat.2020.0852","article-title":"Pharmacodynamic and pharmacokinetic properties of full phosphorothioate small interfering RNAs for gene silencing in vivo","volume":"31","author":"Berk","year":"2021","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/jpet.122.001234_bib21","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3390\/metabo4040977","article-title":"Clinically important features of porphyrin and heme metabolism and the porphyrias","volume":"4","author":"Besur","year":"2014","journal-title":"Metabolites"},{"key":"10.1124\/jpet.122.001234_bib22","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1056\/NEJMra1608634","article-title":"Porphyria","volume":"377","author":"Bissell","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001234_bib23","first-page":"S553","article-title":"A phase 1\/2 open-label extension study of givosiran, an investigational RNAi therapeutic, in patients with acute intermittent porphyria","volume":"73","author":"Bissell","year":"2019","journal-title":"Eur J Neurol"},{"key":"10.1124\/jpet.122.001234_bib24","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00018-019-03317-9","article-title":"Nanoscale delivery systems for microRNAs in cancer therapy","volume":"77","author":"Boca","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"10.1124\/jpet.122.001234_bib25","first-page":"114","article-title":"How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market","volume":"30","author":"Bonneau","year":"2019","journal-title":"EJIFCC"},{"key":"10.1124\/jpet.122.001234_bib26","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1093\/nar\/gkp106","article-title":"A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity","volume":"37","author":"Bramsen","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/jpet.122.001234_bib27","doi-asserted-by":"crossref","first-page":"9128","DOI":"10.1073\/pnas.85.23.9128","article-title":"Evidence for a single rolling circle in the replication of potato spindle tuber viroid","volume":"85","author":"Branch","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.122.001234_bib28","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1126\/science.6197756","article-title":"A replication cycle for viroids and other small infectious RNA\u2019s","volume":"223","author":"Branch","year":"1984","journal-title":"Science"},{"key":"10.1124\/jpet.122.001234_bib29","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2217\/fca-2020-0150","article-title":"Clinical implications and outcomes of the ORION phase III trials","volume":"17","author":"Brandts","year":"2021","journal-title":"Future Cardiol"},{"key":"10.1124\/jpet.122.001234_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102740","article-title":"Bio responsive self-assembly of Au-miRNAs for targeted cancer theranostics","volume":"54","author":"Cai","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1124\/jpet.122.001234_bib31","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Origins and mechanisms of miRNAs and siRNAs","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"key":"10.1124\/jpet.122.001234_bib32","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.3390\/cancers12051246","article-title":"Beyond microRNAs: emerging role of other non-coding RNAs in HPV-driven cancers","volume":"12","author":"Casarotto","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1124\/jpet.122.001234_bib33","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia A and B: molecular and clinical similarities and differences","volume":"104","author":"Castaman","year":"2019","journal-title":"Haematologica"},{"key":"10.1124\/jpet.122.001234_bib34","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3390\/ijms17101712","article-title":"MicroRNA in control of gene expression: an overview of nuclear functions","volume":"17","author":"Catalanotto","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.122.001234_bib35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.omtn.2017.06.005","article-title":"Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine","volume":"8","author":"Chakraborty","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1124\/jpet.122.001234_bib36","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nature09092","article-title":"A dicer-independent miRNA biogenesis pathway that requires Ago catalysis","volume":"465","author":"Cheloufi","year":"2010","journal-title":"Nature"},{"key":"10.1124\/jpet.122.001234_bib37","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1093\/nar\/gkv228","article-title":"A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications","volume":"43","author":"Chen","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/jpet.122.001234_bib38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1021\/acs.accounts.6b00506","article-title":"Surface modification of gold nanoparticles with small molecules for biochemical analysis","volume":"50","author":"Chen","year":"2017","journal-title":"Acc Chem Res"},{"key":"10.1124\/jpet.122.001234_bib39","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1126\/science.1226338","article-title":"Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities","volume":"338","author":"Cheng","year":"2012","journal-title":"Science"},{"key":"10.1124\/jpet.122.001234_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154338","article-title":"The role of peroxisome proliferator-activated receptors (PPAR) in immune responses","volume":"114","author":"Christofides","year":"2021","journal-title":"Metabolism"},{"key":"10.1124\/jpet.122.001234_bib41","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJMra1301564","article-title":"Primary hyperoxaluria","volume":"369","author":"Cochat","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001234_bib42","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001234_bib43","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/gcc.22725","article-title":"Role of miRNAs in immune responses and immunotherapy in cancer","volume":"58","author":"Cortez","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1124\/jpet.122.001234_bib44","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1021\/jacs.6b11273","article-title":"Small molecule inhibition of microRNA-210 reprograms an oncogenic hypoxic circuit","volume":"139","author":"Costales","year":"2017","journal-title":"J Am Chem Soc"},{"key":"10.1124\/jpet.122.001234_bib45","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1021\/bp025755j","article-title":"Small RNA sequences are readily stabilized by inclusion in a carrier rRNA","volume":"19","author":"D\u2019Souza","year":"2003","journal-title":"Biotechnol Prog"},{"key":"10.1124\/jpet.122.001234_bib46","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/s41598-018-20314-3","article-title":"A viroid-derived system to produce large amounts of recombinant RNA in Escherichia coli","volume":"8","author":"Dar\u00f2s","year":"2018","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.122.001234_bib47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/mps4010010","article-title":"Recent advances in miRNA delivery systems","volume":"4","author":"Dasgupta","year":"2021","journal-title":"Methods Protoc"},{"key":"10.1124\/jpet.122.001234_bib48","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrg2968","article-title":"Current prospects for RNA interference-based therapies","volume":"12","author":"Davidson","year":"2011","journal-title":"Nat Rev Genet"},{"key":"10.1124\/jpet.122.001234_bib49","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol Ther"},{"key":"10.1124\/jpet.122.001234_bib50","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1016\/j.apsb.2021.07.027","article-title":"Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo","volume":"11","author":"Deng","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1124\/jpet.122.001234_bib51","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature03049","article-title":"Processing of primary microRNAs by the Microprocessor complex","volume":"432","author":"Denli","year":"2004","journal-title":"Nature"},{"key":"10.1124\/jpet.122.001234_bib52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/ejh.12124","article-title":"Aberrant microRNA expression in multiple myeloma","volume":"91","author":"Dimopoulos","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1124\/jpet.122.001234_bib53","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1242\/jcs.066399","article-title":"Breaking down the barriers: siRNA delivery and endosome escape","volume":"123","author":"Dominska","year":"2010","journal-title":"J Cell Sci"},{"key":"10.1124\/jpet.122.001234_bib54","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1093\/nar\/30.10.e46","article-title":"RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase","volume":"30","author":"Donz\u00e9","year":"2002","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/jpet.122.001234_bib55","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1124\/jpet.122.001234_bib56","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1136\/heartjnl-2012-301924","article-title":"Cardiac transthyretin amyloidosis","volume":"98","author":"Dungu","year":"2012","journal-title":"Heart"},{"key":"10.1124\/jpet.122.001234_bib57","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nmeth1079","article-title":"MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells","volume":"4","author":"Ebert","year":"2007","journal-title":"Nat Methods"},{"key":"10.1124\/jpet.122.001234_bib58","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13046-019-1060-z","article-title":"miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKC\u03b5 and ZEB1 inhibition","volume":"38","author":"El Bezawy","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1124\/jpet.122.001234_bib59","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ejmech.2017.10.011","article-title":"The role of microRNAs in photodynamic therapy of cancer","volume":"142","author":"El-Daly","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1124\/jpet.122.001234_bib60","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.molcel.2008.10.017","article-title":"A human snoRNA with microRNA-like functions","volume":"32","author":"Ender","year":"2008","journal-title":"Mol Cell"},{"key":"10.1124\/jpet.122.001234_bib61","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bcp.2013.09.007","article-title":"Pharmacokinetics","volume":"87","author":"Fan","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.122.001234_bib62","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1124\/jpet.122.001234_bib63","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001234_bib64","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.3390\/cancers12071852","article-title":"A comprehensive review of cancer microRNA therapeutic delivery strategies","volume":"12","author":"Forterre","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1124\/jpet.122.001234_bib65","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","article-title":"Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates","volume":"26","author":"Foster","year":"2018","journal-title":"Mol Ther"},{"key":"10.1124\/jpet.122.001234_bib66","first-page":"56189","article-title":"Protocol for the solid-phase synthesis of oligomers of RNA containing a 2'-O-thiophenylmethyl modification and characterization via circular dichroism","volume":"125","author":"Francis","year":"2017","journal-title":"J Vis Exp"},{"key":"10.1124\/jpet.122.001234_bib67","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/gb-2014-15-4-r57","article-title":"Evidence for the biogenesis of more than 1,000 novel human microRNAs","volume":"15","author":"Friedl\u00e4nder","year":"2014","journal-title":"Genome Biol"},{"key":"10.1124\/jpet.122.001234_bib68","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2215\/CJN.14730920","article-title":"Phase 1\/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial","volume":"16","author":"Frishberg","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/jpet.122.001234_bib69","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s41544-019-0024-y","article-title":"Recent progress in microRNA-based delivery systems for the treatment of human disease","volume":"1","author":"Fu","year":"2019","journal-title":"ExRNA"},{"key":"10.1124\/jpet.122.001234_bib70","doi-asserted-by":"crossref","first-page":"578","DOI":"10.2174\/138955710791384036","article-title":"Recent progress in chemically modified siRNAs","volume":"10","author":"Gaglione","year":"2010","journal-title":"Mini Rev Med Chem"},{"key":"10.1124\/jpet.122.001234_bib71","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/13543784.2017.1274730","article-title":"Recent early clinical drug development for acute kidney injury","volume":"26","author":"Gallagher","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/jpet.122.001234_bib72","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bbrc.2022.02.080","article-title":"RNA interference-based osteoanabolic therapy for osteoporosis by a bone-formation surface targeting delivery system","volume":"601","author":"Gao","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.122.001234_bib73","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001234_bib74","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0022-2836(03)00760-5","article-title":"The tRNA-like domains of E. coli and A. aeolicus transfer-messenger RNA: structural and functional studies","volume":"331","author":"Gaudin","year":"2003","journal-title":"J Mol Biol"},{"key":"10.1124\/jpet.122.001234_bib75","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/nar\/gkt852","article-title":"Miravirsen (SPC3649) can inhibit the biogenesis of miR-122","volume":"42","author":"Gebert","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/jpet.122.001234_bib76","series-title":"Goldman-Cecil Medicine","article-title":"Amyloidosis","author":"Gertz","year":"2016"},{"key":"10.1124\/jpet.122.001234_bib77","series-title":"Package insert","year":"2019"},{"key":"10.1124\/jpet.122.001234_bib78","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00415-019-09602-8","article-title":"Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"267","author":"Gonz\u00e1lez-Duarte","year":"2020","journal-title":"J Neurol"},{"key":"10.1124\/jpet.122.001234_bib79","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1093\/nar\/gkr1174","article-title":"Single-pot enzymatic synthesis of Dicer-substrate siRNAs","volume":"40","author":"Guiley","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/jpet.122.001234_bib80","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.apsb.2016.02.001","article-title":"Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges","volume":"6","author":"Ha","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"10.1124\/jpet.122.001234_bib81","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1124\/jpet.122.001234_bib82","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.122.001234_bib83","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1126\/science.286.5441.950","article-title":"A species of small antisense RNA in posttranscriptional gene silencing in plants","volume":"286","author":"Hamilton","year":"1999","journal-title":"Science"},{"key":"10.1124\/jpet.122.001234_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000484541","article-title":"PIWI proteins and PIWI-interacting RNA: emerging roles in cancer","volume":"44","author":"Han","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"10.1124\/jpet.122.001234_bib85","doi-asserted-by":"crossref","first-page":"16601","DOI":"10.1073\/pnas.1003457107","article-title":"Differential effects of STAT5 and PI3K\/AKT signaling on effector and memory CD8 T-cell survival","volume":"107","author":"Hand","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.122.001234_bib86","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jconrel.2015.03.033","article-title":"Exosomes as drug delivery vehicles for Parkinson\u2019s disease therapy","volume":"207","author":"Haney","year":"2015","journal-title":"J Control Release"},{"key":"10.1124\/jpet.122.001234_bib87","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3389\/fgene.2019.00478","article-title":"The potential for microRNA therapeutics and clinical research","volume":"10","author":"Hanna","year":"2019","journal-title":"Front Genet"},{"key":"10.1124\/jpet.122.001234_bib88","doi-asserted-by":"crossref","first-page":"8485","DOI":"10.1007\/s00253-019-10113-9","article-title":"Construction of Corynebacterium glutamicum cells as containers encapsulating dsRNA overexpressed for agricultural pest control","volume":"103","author":"Hashiro","year":"2019","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1124\/jpet.122.001234_bib89","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jbiosc.2019.03.003","article-title":"Overexpression system for recombinant RNA in Corynebacterium glutamicum using a strong promoter derived from corynephage BFK20","volume":"128","author":"Hashiro","year":"2019","journal-title":"J Biosci Bioeng"},{"key":"10.1124\/jpet.122.001234_bib90","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.molcel.2016.05.026","article-title":"The lupus autoantigen La prevents mis-channeling of tRNA fragments into the human microRNA pathway","volume":"63","author":"Hasler","year":"2016","journal-title":"Mol Cell"},{"key":"10.1124\/jpet.122.001234_bib91","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.molmed.2014.06.005","article-title":"MicroRNAs in cancer: biomarkers, functions and therapy","volume":"20","author":"Hayes","year":"2014","journal-title":"Trends Mol Med"},{"key":"10.1124\/jpet.122.001234_bib92","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.biochi.2013.03.010","article-title":"MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases","volume":"95","author":"He","year":"2013","journal-title":"Biochimie"},{"key":"10.1124\/jpet.122.001234_bib93","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/cdd.2009.56","article-title":"The miR-34 family in cancer and apoptosis","volume":"17","author":"Hermeking","year":"2010","journal-title":"Cell Death Differ"},{"key":"10.1124\/jpet.122.001234_bib94","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1124\/jpet.118.247775","article-title":"Bioengineered noncoding RNAs selectively change cellular miRNome profiles for cancer therapy","volume":"365","author":"Ho","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001234_bib95","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/wrna.1324","article-title":"Bioengineering of noncoding RNAs for research agents and therapeutics","volume":"7","author":"Ho","year":"2016","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"10.1124\/jpet.122.001234_bib96","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1124\/jpet.122.001234_bib97","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s13238-012-2036-3","article-title":"MiR-122 in hepatic function and liver diseases","volume":"3","author":"Hu","year":"2012","journal-title":"Protein Cell"},{"key":"10.1124\/jpet.122.001234_bib98","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nbt.2537","article-title":"Efficient and specific gene knockdown by small interfering RNAs produced in bacteria","volume":"31","author":"Huang","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1124\/jpet.122.001234_bib99","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrg2936","article-title":"Gene silencing by microRNAs: contributions of translational repression and mRNA decay","volume":"12","author":"Huntzinger","year":"2011","journal-title":"Nat Rev Genet"},{"key":"10.1124\/jpet.122.001234_bib100","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nsmb.2931","article-title":"From guide to target: molecular insights into eukaryotic RNA-interference machinery","volume":"22","author":"Ipsaro","year":"2015","journal-title":"Nat Struct Mol Biol"},{"key":"10.1124\/jpet.122.001234_bib101","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41467-018-02989-4","article-title":"Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity","volume":"9","author":"Janas","year":"2018","journal-title":"Nat Commun"},{"key":"10.1124\/jpet.122.001234_bib102","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001234_bib103","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.smim.2015.11.006","article-title":"Enhancing adoptive T cell immunotherapy with microRNA therapeutics","volume":"28","author":"Ji","year":"2016","journal-title":"Semin Immunol"},{"key":"10.1124\/jpet.122.001234_bib104","doi-asserted-by":"crossref","first-page":"30742","DOI":"10.18632\/oncotarget.16372","article-title":"Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models","volume":"8","author":"Jian","year":"2017","journal-title":"Oncotarget"},{"key":"10.1124\/jpet.122.001234_bib105","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1124\/dmd.116.074344","article-title":"Effects of microRNA-34a on the pharmacokinetics of cytochrome P450 probe drugs in mice","volume":"45","author":"Jilek","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.122.001234_bib106","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.omtn.2019.01.007","article-title":"Bioengineered Let-7c inhibits orthotopic hepatocellular carcinoma and improves overall survival with minimal immunogenicity","volume":"14","author":"Jilek","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1124\/jpet.122.001234_bib107","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1089\/nat.2017.0716","article-title":"Current challenges in delivery and cytosolic translocation of therapeutic RNAs","volume":"28","author":"Johannes","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/jpet.122.001234_bib108","doi-asserted-by":"crossref","first-page":"20370","DOI":"10.18632\/oncotarget.4827","article-title":"Simultaneous inhibition of multiple oncogenic miRNAs by a multi-potent microRNA sponge","volume":"6","author":"Jung","year":"2015","journal-title":"Oncotarget"},{"key":"10.1124\/jpet.122.001234_bib109","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2022.01.001","article-title":"Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment","volume":"16","author":"Kallend","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1124\/jpet.122.001234_bib110","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3390\/cells11060983","article-title":"Functional role of microRNAs in regulating cardiomyocyte death","volume":"11","author":"Kansakar","year":"2022","journal-title":"Cells"},{"key":"10.1124\/jpet.122.001234_bib111","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/138920012798356899","article-title":"The ligand nanoparticle conjugation approach for targeted cancer therapy","volume":"13","author":"Karra","year":"2012","journal-title":"Curr Drug Metab"},{"key":"10.1124\/jpet.122.001234_bib112","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/php.12857","article-title":"Cell death pathways associated with photodynamic therapy: an update","volume":"94","author":"Kessel","year":"2018","journal-title":"Photochem Photobiol"},{"key":"10.1124\/jpet.122.001234_bib113","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp1614154","article-title":"Oligonucleotide therapeutics \u2013 a new class of cholesterol-lowering drugs","volume":"376","author":"Khvorova","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001234_bib114","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0092-8674(03)00801-8","article-title":"Functional siRNAs and miRNAs exhibit strand bias","volume":"115","author":"Khvorova","year":"2003","journal-title":"Cell"},{"key":"10.1124\/jpet.122.001234_bib115","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1124\/jpet.122.001234_bib116","doi-asserted-by":"crossref","DOI":"10.1093\/femsle\/fnx268","article-title":"Extracellular nucleic acids of the marine bacterium Rhodovulum sulfidophilum and recombinant RNA production technology using bacteria","volume":"365","author":"Kikuchi","year":"2018","journal-title":"FEMS Microbiol Lett"},{"key":"10.1124\/jpet.122.001234_bib117","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1021\/acs.bioconjchem.0c00268","article-title":"Investigational therapies for primary hyperoxaluria","volume":"31","author":"Kletzmayr","year":"2020","journal-title":"Bioconjug Chem"},{"key":"10.1124\/jpet.122.001234_bib118","series-title":"StatPearls","article-title":"Acute hepatic porphyria","author":"Kothadia","year":"2022"},{"key":"10.1124\/jpet.122.001234_bib119","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/nmt-2018-0033","article-title":"Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"9","author":"Kristen","year":"2019","journal-title":"Neurodegener Dis Manag"},{"key":"10.1124\/jpet.122.001234_bib120","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.tig.2018.11.005","article-title":"Small nucleolar RNAs tell a different tale","volume":"35","author":"Kufel","year":"2019","journal-title":"Trends Genet"},{"key":"10.1124\/jpet.122.001234_bib121","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.2174\/138161282131151013190112","article-title":"Exosomes: natural carriers for siRNA delivery","volume":"21","author":"Kumar","year":"2015","journal-title":"Curr Pharm Des"},{"key":"10.1124\/jpet.122.001234_bib122","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12915-014-0078-0","article-title":"Meta-analysis of tRNA derived RNA fragments reveals that they are evolutionarily conserved and associate with AGO proteins to recognize specific RNA targets","volume":"12","author":"Kumar","year":"2014","journal-title":"BMC Biol"},{"key":"10.1124\/jpet.122.001234_bib123","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1261\/rna.066126.118","article-title":"tRNA fragments (tRFs) guide Ago to regulate gene expression post-transcriptionally in a Dicer-independent manner","volume":"24","author":"Kuscu","year":"2018","journal-title":"RNA"},{"key":"10.1124\/jpet.122.001234_bib124","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.ymthe.2018.05.016","article-title":"Specific inhibition of hepatic lactate dehydrogenase reduces oxalate production in mouse models of primary hyperoxaluria","volume":"26","author":"Lai","year":"2018","journal-title":"Mol Ther"},{"key":"10.1124\/jpet.122.001234_bib125","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/637850","article-title":"Comparison between the repression potency of siRNA targeting the coding region and the 3\u2032-untranslated region of mRNA","volume":"2013","author":"Lai","year":"2013","journal-title":"BioMed Res Int"},{"key":"10.1124\/jpet.122.001234_bib126","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1124\/jpet.122.001234_bib127","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","article-title":"The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14","volume":"75","author":"Lee","year":"1993","journal-title":"Cell"},{"key":"10.1124\/jpet.122.001234_bib128","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/gt.2011.100","article-title":"Chemical modification and design of anti-miRNA oligonucleotides","volume":"18","author":"Lennox","year":"2011","journal-title":"Gene Ther"},{"key":"10.1124\/jpet.122.001234_bib129","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1038\/mtna.2013.46","article-title":"Improved performance of anti-miRNA oligonucleotides using a novel non-nucleotide modifier","volume":"2","author":"Lennox","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1124\/jpet.122.001234_bib130","series-title":"Package insert","year":"2021"},{"key":"10.1124\/jpet.122.001234_bib131","doi-asserted-by":"crossref","first-page":"18440","DOI":"10.1021\/jp303267y","article-title":"Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core","volume":"116","author":"Leung","year":"2012","journal-title":"J Phys Chem C Nanomater Interfaces"},{"key":"10.1124\/jpet.122.001234_bib132","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/B978-0-12-800148-6.00004-3","article-title":"Lipid nanoparticles for short interfering RNA delivery","volume":"88","author":"Leung","year":"2014","journal-title":"Adv Genet"},{"key":"10.1124\/jpet.122.001234_bib133","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1124\/dmd.115.064493","article-title":"Chimeric microRNA-1291 biosynthesized efficiently in Escherichia coli is effective to reduce target gene expression in human carcinoma cells and improve chemosensitivity","volume":"43","author":"Li","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.122.001234_bib134","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1124\/dmd.114.060145","article-title":"Rapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells","volume":"42","author":"Li","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.122.001234_bib135","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.7150\/thno.56596","article-title":"In vivo fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapy","volume":"11","author":"Li","year":"2021","journal-title":"Theranostics"},{"key":"10.1124\/jpet.122.001234_bib136","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3390\/genes9050246","article-title":"tRNA-derived small RNA: a novel regulatory small non-coding RNA","volume":"9","author":"Li","year":"2018","journal-title":"Genes (Basel)"},{"key":"10.1124\/jpet.122.001234_bib137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygeno.2010.03.009","article-title":"Identification of homologous microRNAs in 56 animal genomes","volume":"96","author":"Li","year":"2010","journal-title":"Genomics"},{"key":"10.1124\/jpet.122.001234_bib138","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.apsb.2018.12.002","article-title":"Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition via the regulation of target ADME gene expression","volume":"9","author":"Li","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"10.1124\/jpet.122.001234_bib139","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1681\/ASN.2016030338","article-title":"An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria","volume":"28","author":"Liebow","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.122.001234_bib140","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/15476286.2018.1445959","article-title":"Anti-miRNA oligonucleotides: a comprehensive guide for design","volume":"15","author":"Lima","year":"2018","journal-title":"RNA Biol"},{"key":"10.1124\/jpet.122.001234_bib141","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2012.08.014","article-title":"Single-stranded siRNAs activate RNAi in animals","volume":"150","author":"Lima","year":"2012","journal-title":"Cell"},{"key":"10.1124\/jpet.122.001234_bib142","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1083\/jcb.201208082","article-title":"Discovering the first microRNA-targeted drug","volume":"199","author":"Lindow","year":"2012","journal-title":"J Cell Biol"},{"key":"10.1124\/jpet.122.001234_bib143","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/bfgp\/elz002","article-title":"Interplay between miRNAs and host genes and their role in cancer","volume":"18","author":"Liu","year":"2018","journal-title":"Brief Funct Genomics"},{"key":"10.1124\/jpet.122.001234_bib144","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1472-6750-10-85","article-title":"DNAzyme-mediated recovery of small recombinant RNAs from a 5S rRNA-derived chimera expressed in Escherichia coli","volume":"10","author":"Liu","year":"2010","journal-title":"BMC Biotechnol"},{"key":"10.1124\/jpet.122.001234_bib145","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.4161\/cc.7.16.6533","article-title":"Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer","volume":"7","author":"Lodygin","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1124\/jpet.122.001234_bib146","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/nchem.907","article-title":"Graphene oxide as a chemically tunable platform for optical applications","volume":"2","author":"Loh","year":"2010","journal-title":"Nat Chem"},{"key":"10.1124\/jpet.122.001234_bib147","doi-asserted-by":"crossref","first-page":"32301","DOI":"10.1038\/srep32301","article-title":"Enhancing endosomal escape for intracellular delivery of macromolecular biologic therapeutics","volume":"6","author":"L\u00f6nn","year":"2016","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.122.001234_bib148","doi-asserted-by":"crossref","first-page":"12332","DOI":"10.1073\/pnas.2003597117","article-title":"Combined loss of function of two different loci of miR-15\/16 drives the pathogenesis of acute myeloid leukemia","volume":"117","author":"Lovat","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.122.001234_bib149","first-page":"1","article-title":"Exosome-based small RNA delivery: progress and prospects","volume":"13","author":"Lu","year":"2018","journal-title":"Asian J Pharm Sci"},{"key":"10.1124\/jpet.122.001234_bib150","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/JBM.S159297","article-title":"An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B","volume":"9","author":"Machin","year":"2018","journal-title":"J Blood Med"},{"key":"10.1124\/jpet.122.001234_bib151","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/cbic.202000009","article-title":"Developments in siRNA modification and ligand conjugated delivery to enhance RNA interference ability","volume":"21","author":"vMaguregui","year":"2020","journal-title":"ChemBioChem"},{"key":"10.1124\/jpet.122.001234_bib152","first-page":"85","article-title":"Acute kidney injury: definition, pathophysiology and clinical phenotypes","volume":"37","author":"Makris","year":"2016","journal-title":"Clin Biochem Rev"},{"key":"10.1124\/jpet.122.001234_bib153","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.addr.2012.07.018","article-title":"Mesoporous silica nanoparticles in medicine--recent advances","volume":"65","author":"Mamaeva","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/jpet.122.001234_bib154","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013225","article-title":"Diagnosis and treatment of heterozygous familial hypercholesterolemia","volume":"8","author":"McGowan","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1124\/jpet.122.001234_bib155","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt.3078","article-title":"Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications","volume":"32","author":"Meade","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1124\/jpet.122.001234_bib156","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1042\/BST20140142","article-title":"Regulation of miRNA strand selection: follow the leader?","volume":"42","author":"Meijer","year":"2014","journal-title":"Biochem Soc Trans"},{"key":"10.1124\/jpet.122.001234_bib157","doi-asserted-by":"crossref","first-page":"8095","DOI":"10.1093\/nar\/16.16.8095","article-title":"Fast purification of a functional elongator tRNAmet expressed from a synthetic gene in vivo","volume":"16","author":"Meinnel","year":"1988","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/jpet.122.001234_bib158","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3389\/fimmu.2017.00331","article-title":"RNA interference-induced innate immunity, off-target effect, or immune adjuvant?","volume":"8","author":"Meng","year":"2017","journal-title":"Front Immunol"},{"key":"10.1124\/jpet.122.001234_bib159","doi-asserted-by":"crossref","first-page":"7167","DOI":"10.1039\/D0CS00560F","article-title":"Small molecule recognition of disease-relevant RNA structures","volume":"49","author":"Meyer","year":"2020","journal-title":"Chem Soc Rev"},{"key":"10.1124\/jpet.122.001234_bib160","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2174\/0929867013372391","article-title":"Backbone modification of nucleic acids: synthesis, structure and therapeutic applications","volume":"8","author":"Micklefield","year":"2001","journal-title":"Curr Med Chem"},{"key":"10.1124\/jpet.122.001234_bib161","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.omtn.2017.11.003","article-title":"Function control of anti-microRNA oligonucleotides using interstrand cross-linked duplexes","volume":"10","author":"Mie","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1124\/jpet.122.001234_bib162","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1038\/mtna.2014.47","article-title":"Mir-34: a new weapon against cancer?","volume":"3","author":"Misso","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1124\/jpet.122.001234_bib163","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"Suppl 6","key":"10.1124\/jpet.122.001234_bib164","doi-asserted-by":"crossref","first-page":"S1262","DOI":"10.21037\/tcr.2016.11.37","article-title":"MicroRNAs as novel elements in personalized radiotherapy","volume":"5","author":"Moertl","year":"2016","journal-title":"Transl Cancer Res"},{"key":"10.1124\/jpet.122.001234_bib165","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1681\/ASN.2008111204","article-title":"siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury","volume":"20","author":"Molitoris","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.122.001234_bib166","doi-asserted-by":"crossref","first-page":"12369","DOI":"10.1002\/jcp.28058","article-title":"MicroRNA replacement therapy in cancer","volume":"234","author":"Mollaei","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1124\/jpet.122.001234_bib167","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.15252\/emmm.201303604","article-title":"MicroRNA mimicry blocks pulmonary fibrosis","volume":"6","author":"Montgomery","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1124\/jpet.122.001234_bib168","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3390\/genes9070329","article-title":"Above the epitranscriptome: RNA modifications and stem cell identity","volume":"9","author":"Morena","year":"2018","journal-title":"Genes (Basel)"},{"key":"10.1124\/jpet.122.001234_bib169","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/13543784.2018.1457647","article-title":"Tivanisiran, a novel siRNA for the treatment of dry eye disease","volume":"27","author":"Moreno-Monta\u00f1\u00e9s","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/jpet.122.001234_bib170","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nbt792","article-title":"Recombinant Dicer efficiently converts large dsRNAs into siRNAs suitable for gene silencing","volume":"21","author":"Myers","year":"2003","journal-title":"Nat Biotechnol"},{"key":"10.1124\/jpet.122.001234_bib171","doi-asserted-by":"crossref","DOI":"10.1128\/genomeA.00388-15","article-title":"Complete genome sequence of Rhodovulum sulfidophilum DSM 2351, an extracellular nucleic acid-producing bacterium","volume":"3","author":"Nagao","year":"2015","journal-title":"Genome Announc"},{"key":"10.1124\/jpet.122.001234_bib172","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2323\/jgam.60.222","article-title":"Short hairpin RNAs of designed sequences can be extracellularly produced by the marine bacterium Rhodovulum sulfidophilum","volume":"60","author":"Nagao","year":"2014","journal-title":"J Gen Appl Microbiol"},{"key":"10.1124\/jpet.122.001234_bib173","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J Am Chem Soc"},{"key":"10.1124\/jpet.122.001234_bib174","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2307\/3869076","article-title":"Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans","volume":"2","author":"Napoli","year":"1990","journal-title":"Plant Cell"},{"key":"10.1124\/jpet.122.001234_bib175","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1093\/nar\/gks292","article-title":"Fast production of homogeneous recombinant RNA--towards large-scale production of RNA","volume":"40","author":"Nelissen","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/jpet.122.001234_bib176","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/ijms19010065","article-title":"Development of novel therapeutic agents by inhibition of oncogenic microRNAs","volume":"19","author":"Nguyen","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.122.001234_bib177","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/13506129.2020.1730790","article-title":"Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"27","author":"Obici","year":"2020","journal-title":"Amyloid"},{"key":"10.1124\/jpet.122.001234_bib178","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/mt.2012.180","article-title":"Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells","volume":"21","author":"Ohno","year":"2013","journal-title":"Mol Ther"},{"key":"10.1124\/jpet.122.001234_bib179","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1126\/science.1178705","article-title":"A high-resolution structure of the pre-microRNA nuclear export machinery","volume":"326","author":"Okada","year":"2009","journal-title":"Science"},{"key":"10.1124\/jpet.122.001234_bib180","series-title":"Package insert.","year":"2018"},{"key":"10.1124\/jpet.122.001234_bib181","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1080\/15384101.2019.1634956","article-title":"Identification and validation of microRNAs that synergize with miR-34a - a basis for combinatorial microRNA therapeutics","volume":"18","author":"Orellana","year":"2019","journal-title":"Cell Cycle"},{"key":"10.1124\/jpet.122.001234_bib182","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2007.12.7878","article-title":"Hypoxic radiosensitization: adored and ignored","volume":"25","author":"Overgaard","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.122.001234_bib183","series-title":"Package insert.","year":"2020"},{"key":"10.1124\/jpet.122.001234_bib184","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/ckj\/sfx146","article-title":"Porphyria and kidney diseases","volume":"11","author":"Pallet","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1124\/jpet.122.001234_bib185","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1124\/dmd.113.052092","article-title":"Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1","volume":"41","author":"Pan","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.122.001234_bib186","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/35040556","article-title":"Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA","volume":"408","author":"Pasquinelli","year":"2000","journal-title":"Nature"},{"key":"10.1124\/jpet.122.001234_bib187","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41523-017-0032-8","article-title":"Human snoRNA-93 is processed into a microRNA-like RNA that promotes breast cancer cell invasion","volume":"3","author":"Patterson","year":"2017","journal-title":"NPJ Breast Cancer"},{"key":"10.1124\/jpet.122.001234_bib188","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat Rev Genet"},{"key":"10.1124\/jpet.122.001234_bib189","article-title":"Co-expression and co-purification of archaeal and eukaryal box C\/D RNPs","volume":"9","author":"Peng","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/jpet.122.001234_bib190","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1080\/21655979.2017.1284710","article-title":"New insights for therapeutic recombinant human miRNAs heterologous production: Rhodovolum sulfidophilum vs Escherichia coli","volume":"8","author":"Pereira","year":"2017","journal-title":"Bioengineered"},{"key":"10.1124\/jpet.122.001234_bib191","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1007\/s00253-016-7350-x","article-title":"Advances in time course extracellular production of human pre-miR-29b from Rhodovulum sulfidophilum","volume":"100","author":"Pereira","year":"2016","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1124\/jpet.122.001234_bib192","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114392","article-title":"Single bioengineered ncRNA molecule for dual-targeting toward the control of non-small cell lung cancer patient-derived xenograft tumor growth","volume":"189","author":"Petrek","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.122.001234_bib193","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1007\/s00204-016-1815-7","article-title":"MicroRNA epigenetic signatures in human disease","volume":"90","author":"Pileti\u010d","year":"2016","journal-title":"Arch Toxicol"},{"key":"10.1124\/jpet.122.001234_bib194","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1128\/aem.61.10.3661-3666.1995","article-title":"A novel approach for monitoring genetically engineered microorganisms by using artificial, stable RNAs","volume":"61","author":"Pitulle","year":"1995","journal-title":"Appl Environ Microbiol"},{"key":"10.1124\/jpet.122.001234_bib195","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/nprot.2009.67","article-title":"A generic protocol for the expression and purification of recombinant RNA in Escherichia coli using a tRNA scaffold","volume":"4","author":"Ponchon","year":"2009","journal-title":"Nat Protoc"},{"key":"10.1124\/jpet.122.001234_bib196","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nmeth1058","article-title":"Recombinant RNA technology: the tRNA scaffold","volume":"4","author":"Ponchon","year":"2007","journal-title":"Nat Methods"},{"key":"10.1124\/jpet.122.001234_bib197","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1094\/MPMI.2002.15.3.269","article-title":"Tombusvirus P19-mediated suppression of virus-induced gene silencing is controlled by genetic and dosage features that influence pathogenicity","volume":"15","author":"Qiu","year":"2002","journal-title":"Mol Plant Microbe Interact"},{"key":"10.1124\/jpet.122.001234_bib198","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001234_bib199","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001234_bib200","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001234_bib201","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwac025","article-title":"Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia","author":"Reijman","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1124\/jpet.122.001234_bib202","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/sj.mt.6300240","article-title":"2\u2032-O-methyl-modified RNAs act as TLR7 antagonists","volume":"15","author":"Robbins","year":"2007","journal-title":"Mol Ther"},{"key":"10.1124\/jpet.122.001234_bib203","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nature05983","article-title":"Intronic microRNA precursors that bypass Drosha processing","volume":"448","author":"Ruby","year":"2007","journal-title":"Nature"},{"key":"10.1124\/jpet.122.001234_bib204","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1093\/ehjcvp\/pvab014","article-title":"Inclisiran: a new milestone on the PCSK9 road to tackle cardiovascular risk","volume":"7","author":"Santulli","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1124\/jpet.122.001234_bib205","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/joim.13443","article-title":"RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria","volume":"291","author":"Sardh","year":"2022","journal-title":"J Intern Med"},{"key":"10.1124\/jpet.122.001234_bib206","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa1807838","article-title":"Phase 1 trial of an RNA interference therapy for acute intermittent porphyria","volume":"380","author":"Sardh","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001234_bib207","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.gim.2021.10.024","article-title":"Phase 3 trial of lumasiran for primary hyperoxaluria type 1: a new RNAi therapeutic in infants and young children","volume":"24","author":"Sas","year":"2021","journal-title":"Genet Med"},{"key":"10.1124\/jpet.122.001234_bib208","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: first approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"10.1124\/jpet.122.001234_bib209","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: first approval","volume":"81","author":"Scott","year":"2021","journal-title":"Drugs"},{"key":"10.1124\/jpet.122.001234_bib210","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/17460441.2020.1765770","article-title":"Challenges identifying efficacious miRNA therapeutics for cancer","volume":"15","author":"Segal","year":"2020","journal-title":"Expert Opin Drug Discov"},{"key":"10.1124\/jpet.122.001234_bib211","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat Med"},{"key":"10.1124\/jpet.122.001234_bib212","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1096\/fj.06-6014rev","article-title":"A brief history of RNAi: the silence of the genes","volume":"20","author":"Sen","year":"2006","journal-title":"FASEB J"},{"key":"10.1124\/jpet.122.001234_bib213","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1172\/JCI125228","article-title":"Selective tissue targeting of synthetic nucleic acid drugs","volume":"129","author":"Seth","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.122.001234_bib214","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.122.001234_bib215","doi-asserted-by":"crossref","first-page":"DES7","DOI":"10.1167\/iovs.17-23475","article-title":"Definition and diagnostic criteria of dry eye disease: historical overview and future directions","volume":"59","author":"Shimazaki","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.122.001234_bib216","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/msj.21352","article-title":"Amyloid neuropathies","volume":"79","author":"Shin","year":"2012","journal-title":"Mt Sinai J Med"},{"key":"10.1124\/jpet.122.001234_bib217","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1478-811X-11-88","article-title":"Exosomes are natural carriers of exogenous siRNA to human cells in vitro","volume":"11","author":"Shtam","year":"2013","journal-title":"Cell Commun Signal"},{"key":"10.1124\/jpet.122.001234_bib218","first-page":"v","article-title":"Preface","volume":"1364","author":"Shum","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1124\/jpet.122.001234_bib219","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/emboj\/cdf312","article-title":"A viral protein suppresses RNA silencing and binds silencing-generated, 21- to 25-nucleotide double-stranded RNAs","volume":"21","author":"Silhavy","year":"2002","journal-title":"EMBO J"},{"key":"10.1124\/jpet.122.001234_bib220","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3390\/cancers14061588","article-title":"Clinical Applications of short non-coding RNA-based therapies in the era of precision medicine","volume":"14","author":"Smith","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1124\/jpet.122.001234_bib221","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1124\/jpet.122.001234_bib222","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1758-907X-3-1","article-title":"Inhibition of microRNA function by antimiR oligonucleotides","volume":"3","author":"Stenvang","year":"2012","journal-title":"Silence"},{"key":"10.1124\/jpet.122.001234_bib223","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1124\/jpet.122.001234_bib224","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7150\/thno.16357","article-title":"Targeting and regulating of an oncogene via nanovector delivery of microRNA using patient-derived xenografts","volume":"7","author":"Sun","year":"2017","journal-title":"Theranostics"},{"key":"10.1124\/jpet.122.001234_bib225","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1128\/AEM.01971-09","article-title":"Extracellular production of an RNA aptamer by ribonuclease-free marine bacteria harboring engineered plasmids: a proposal for industrial RNA drug production","volume":"76","author":"Suzuki","year":"2010","journal-title":"Appl Environ Microbiol"},{"key":"10.1124\/jpet.122.001234_bib226","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","article-title":"A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects","volume":"32","author":"Taylor","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1124\/jpet.122.001234_bib227","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/nat.2012.0371","article-title":"Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration","volume":"22","author":"Thompson","year":"2012","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/jpet.122.001234_bib228","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1423-0127-20-99","article-title":"MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy","volume":"20","author":"To","year":"2013","journal-title":"J Biomed Sci"},{"key":"10.1124\/jpet.122.001234_bib229","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.3748\/wjg.v24.i27.2949","article-title":"MicroRNAs in the prognosis and therapy of colorectal cancer: from bench to bedside","volume":"24","author":"To","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1124\/jpet.122.001234_bib230","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/17460441.2020.1690449","article-title":"Advances in the discovery of microRNA-based anticancer therapeutics: latest tools and developments","volume":"15","author":"To","year":"2020","journal-title":"Expert Opin Drug Discov"},{"key":"10.1124\/jpet.122.001234_bib231","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1124\/molpharm.120.000130","article-title":"MicroRNA-1291-5p sensitizes pancreatic carcinoma cells to arginine deprivation and chemotherapy through the regulation of arginolysis and glycolysis","volume":"98","author":"Tu","year":"2020","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.122.001234_bib232","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.canlet.2018.10.038","article-title":"Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models","volume":"442","author":"Tu","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1124\/jpet.122.001234_bib233","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1158\/0008-5472.CAN-19-0656","article-title":"A novel bioengineered miR-127 prodrug suppresses the growth and metastatic potential of triple-negative breast cancer cells","volume":"80","author":"Umeh-Garcia","year":"2020","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.122.001234_bib234","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/970607","article-title":"Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation","volume":"2014","author":"Valinezhad Orang","year":"2014","journal-title":"Int J Genomics"},{"key":"10.1124\/jpet.122.001234_bib235","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/17512433.2020.1787832","article-title":"Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review","volume":"13","author":"van Bruggen","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1124\/jpet.122.001234_bib236","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nbt.1830","article-title":"siRNA delivery with exosome nanoparticles","volume":"29","author":"van den Boorn","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1124\/jpet.122.001234_bib237","first-page":"1","article-title":"Viral vectors: a look back and ahead on gene transfer technology","volume":"36","author":"Vannucci","year":"2013","journal-title":"New Microbiol"},{"key":"10.1124\/jpet.122.001234_bib238","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.863238","article-title":"Cardiac remodeling after myocardial infarction: functional contribution of microRNAs to inflammation and fibrosis","volume":"9","author":"Varzideh","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1124\/jpet.122.001234_bib239","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/wrna.121","article-title":"Posttranscriptional upregulation by microRNAs","volume":"3","author":"Vasudevan","year":"2012","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"10.1124\/jpet.122.001234_bib240","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nchembio.1452","article-title":"Sequence-based design of bioactive small molecules that target precursor microRNAs","volume":"10","author":"Velagapudi","year":"2014","journal-title":"Nat Chem Biol"},{"key":"10.1124\/jpet.122.001234_bib241","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/liv.15090","article-title":"Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study","volume":"42","author":"Ventura","year":"2022","journal-title":"Liver Int"},{"key":"10.1124\/jpet.122.001234_bib242","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1124\/jpet.115.225631","article-title":"Bioengineering novel chimeric microRNA-34a for prodrug cancer therapy: high-yield expression and purification, and structural and functional characterization","volume":"354","author":"Wang","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001234_bib243","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-60761-863-8_3","article-title":"The principles of MiRNA-masking antisense oligonucleotides technology","volume":"676","author":"Wang","year":"2011","journal-title":"Methods Mol Biol"},{"key":"10.1124\/jpet.122.001234_bib244","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/08916934.2022.2051142","article-title":"Inclisiran inhibits oxidized low-density lipoprotein-induced foam cell formation in Raw264.7 macrophages via activating the PPAR\u03b3 pathway","volume":"55","author":"Wang","year":"2022","journal-title":"Autoimmunity"},{"key":"10.1124\/jpet.122.001234_bib245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1008755","article-title":"Network potential identifies therapeutic miRNA cocktails in Ewing sarcoma","volume":"17","author":"Weaver","year":"2021","journal-title":"PLOS Comput Biol"},{"key":"10.1124\/jpet.122.001234_bib246","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biotechadv.2019.04.012","article-title":"RNAi therapeutic and its innovative biotechnological evolution","volume":"37","author":"Weng","year":"2019","journal-title":"Biotechnol Adv"},{"key":"10.1124\/jpet.122.001234_bib247","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.biochi.2011.06.017","article-title":"Mirtrons: microRNA biogenesis via splicing","volume":"93","author":"Westholm","year":"2011","journal-title":"Biochimie"},{"key":"10.1124\/jpet.122.001234_bib248","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/35000016","article-title":"Specific interference with gene function by double-stranded RNA in early mouse development","volume":"2","author":"Wianny","year":"2000","journal-title":"Nat Cell Biol"},{"key":"10.1124\/jpet.122.001234_bib249","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/0092-8674(93)90530-4","article-title":"Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans","volume":"75","author":"Wightman","year":"1993","journal-title":"Cell"},{"key":"10.1124\/jpet.122.001234_bib250","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cbpa.2006.10.001","article-title":"Building oligonucleotide therapeutics using non-natural chemistries","volume":"10","author":"Wilson","year":"2006","journal-title":"Curr Opin Chem Biol"},{"key":"10.1124\/jpet.122.001234_bib251","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.canlet.2017.09.043","article-title":"Favorable biodistribution, specific targeting and conditional endosomal escape of RNA nanoparticles in cancer therapy","volume":"414","author":"Xu","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1124\/jpet.122.001234_bib252","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.biomaterials.2019.04.025","article-title":"Creatine based polymer for codelivery of bioengineered microRNA and chemodrugs against breast cancer lung metastasis","volume":"210","author":"Xu","year":"2019","journal-title":"Biomaterials"},{"key":"10.1124\/jpet.122.001234_bib253","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/onc.2015.96","article-title":"MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity","volume":"35","author":"Xue","year":"2016","journal-title":"Oncogene"},{"key":"10.1124\/jpet.122.001234_bib254","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/17460441.2017.1263298","article-title":"MicroRNA-targeted therapeutics for lung cancer treatment","volume":"12","author":"Xue","year":"2017","journal-title":"Expert Opin Drug Discov"},{"key":"10.1124\/jpet.122.001234_bib255","doi-asserted-by":"crossref","first-page":"9942","DOI":"10.1073\/pnas.152327299","article-title":"Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate effective RNA interference in mammalian cells","volume":"99","author":"Yang","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.122.001234_bib256","doi-asserted-by":"crossref","first-page":"15163","DOI":"10.1073\/pnas.1006432107","article-title":"Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis","volume":"107","author":"Yang","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.122.001234_bib257","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.apsb.2019.11.001","article-title":"Bioengineered miR-328-3p modulates GLUT1-mediated glucose uptake and metabolism to exert synergistic antiproliferative effects with chemotherapeutics","volume":"10","author":"Yi","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1124\/jpet.122.001234_bib258","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nsmb.1733","article-title":"ATP-dependent human RISC assembly pathways","volume":"17","author":"Yoda","year":"2010","journal-title":"Nat Struct Mol Biol"},{"key":"10.1124\/jpet.122.001234_bib259","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00253-020-10350-3","article-title":"Novel approaches for efficient in vivo fermentation production of noncoding RNAs","volume":"104","author":"Yu","year":"2020","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1124\/jpet.122.001234_bib260","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/pr.120.019554","article-title":"RNA drugs and RNA targets for small molecules: principles, progress, and challenges","volume":"72","author":"Yu","year":"2020","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.122.001234_bib261","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pharmthera.2018.11.011","article-title":"RNA therapy: are we using the right molecules?","volume":"196","author":"Yu","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.122.001234_bib262","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1124\/dmd.115.067470","article-title":"MicroRNA pharmacoepigenetics: posttranscriptional regulation mechanisms behind variable drug disposition and strategy to develop more effective therapy","volume":"44","author":"Yu","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.122.001234_bib263","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107967","article-title":"Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination","volume":"230","author":"Yu","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.122.001234_bib264","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cell.2004.06.017","article-title":"Single processing center models for human Dicer and bacterial RNase III","volume":"118","author":"Zhang","year":"2004","journal-title":"Cell"},{"key":"10.1124\/jpet.122.001234_bib265","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.122.001234_bib266","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijpharm.2018.06.026","article-title":"Lipidation of polyethylenimine-based polyplex increases serum stability of bioengineered RNAi agents and offers more consistent tumoral gene knockdown in vivo","volume":"547","author":"Zhang","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1124\/jpet.122.001234_bib267","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2147\/DDDT.S288859","article-title":"The risks of miRNA therapeutics: in a drug target perspective","volume":"15","author":"Zhang","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/jpet.122.001234_bib268","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jcph.1553","article-title":"Pharmacokinetics of patisiran, the first approved RNA interference therapy in patients with hereditary transthyretin-mediated amyloidosis","volume":"60","author":"Zhang","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.122.001234_bib269","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/jmr.917","article-title":"Engineered 5S ribosomal RNAs displaying aptamers recognizing vascular endothelial growth factor and malachite green","volume":"22","author":"Zhang","year":"2009","journal-title":"J Mol Recognit"},{"key":"10.1124\/jpet.122.001234_bib270","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1515\/hsz-2016-0308","article-title":"MicroRNAs are important regulators of drug resistance in colorectal cancer","volume":"398","author":"Zhang","year":"2017","journal-title":"Biol Chem"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524003811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524003811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.122.001234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T11:51:50Z","timestamp":1740657110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524003811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":270,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0022356524003811"],"URL":"https:\/\/doi.org\/10.1124\/jpet.122.001234","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.122.001234","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The Author(s)","name":"copyright","label":"Copyright"}]}}